SBEV SCHEDULE 13G: SEC filing
Filed with the SEC on · accession 0000919574-26-007133
SBEV filed a SCHEDULE 13G (schedule 13g) with the SEC on Oct 22, 2026. C/M Capital Master Fund, LP, C/M Capital Partners, LP, Thomas Walsh, and Jonathan Juchno filed a joint Schedule 13G indicating a passive ownership position in Endovia Health Sciences, Inc. (EDVA).
Summary of the filing
C/M Capital Master Fund, LP, C/M Capital Partners, LP, Thomas Walsh, and Jonathan Juchno filed a joint Schedule 13G indicating a passive ownership position in Endovia Health Sciences, Inc. (EDVA). The filing includes a joint filing agreement dated October 22, 2026.
Key details
✦ Ask GOAX AI about this filing — what it means for SBEV, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SBEV?
Click hereFrequently asked questions
What did SBEV file with the SEC on Oct 22, 2026?
SBEV filed a SCHEDULE 13G (SEC filing). C/M Capital Master Fund, LP, C/M Capital Partners, LP, Thomas Walsh, and Jonathan Juchno filed a joint Schedule 13G indicating a passive ownership position in Endovia Health Sciences, Inc. (EDVA). The filing includes a joint filing agreement dated October 22, 2026.
How do I read a SCHEDULE 13G?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).
Other SBEV SEC filings
- 424B3 · Shelf registrationNov 4, 2026
- EFFECT · SEC filingNov 3, 2026
- DEF 14A · Stock splitNov 2, 2026
- S-1 · Shelf registrationOct 27, 2026
- 8-K · Material agreementOct 27, 2026
- 8-K · Material agreementOct 15, 2026
- 8-K · Secondary offeringOct 6, 2026
- 8-K · Fda approvalOct 5, 2026
- DEF 14A · Board changeOct 5, 2026
- 8-K · Material agreementSep 24, 2026
Get alerts when SBEV files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days